JP2011509248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509248A5 JP2011509248A5 JP2010540923A JP2010540923A JP2011509248A5 JP 2011509248 A5 JP2011509248 A5 JP 2011509248A5 JP 2010540923 A JP2010540923 A JP 2010540923A JP 2010540923 A JP2010540923 A JP 2010540923A JP 2011509248 A5 JP2011509248 A5 JP 2011509248A5
- Authority
- JP
- Japan
- Prior art keywords
- res
- compound
- cancer
- leucine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 229940024606 amino acid Drugs 0.000 claims 17
- 235000001014 amino acid Nutrition 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 11
- 125000002947 alkylene group Chemical group 0.000 claims 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 9
- 235000004279 alanine Nutrition 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 8
- 150000002576 ketones Chemical class 0.000 claims 8
- 239000004471 Glycine Substances 0.000 claims 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 6
- 229960000310 isoleucine Drugs 0.000 claims 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 6
- 230000002062 proliferating effect Effects 0.000 claims 6
- 239000004475 Arginine Substances 0.000 claims 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- 235000009582 asparagine Nutrition 0.000 claims 5
- 229960001230 asparagine Drugs 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000004474 valine Substances 0.000 claims 5
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 claims 4
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 claims 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 3
- 239000004472 Lysine Substances 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- -1 amino, hydroxyl Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000001033 ether group Chemical group 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 230000000683 nonmetastatic effect Effects 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 150000003862 amino acid derivatives Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001198 duodenum Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 210000001630 jejunum Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US938207P | 2007-12-28 | 2007-12-28 | |
| PCT/US2008/088438 WO2009086516A1 (en) | 2007-12-28 | 2008-12-29 | Anti-proliferative compounds and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014264770A Division JP2015110590A (ja) | 2007-12-28 | 2014-12-26 | 抗細胞増殖化合物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011509248A JP2011509248A (ja) | 2011-03-24 |
| JP2011509248A5 true JP2011509248A5 (enExample) | 2011-10-13 |
Family
ID=40568120
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540923A Pending JP2011509248A (ja) | 2007-12-28 | 2008-12-29 | 抗細胞増殖化合物およびその使用方法 |
| JP2014264770A Pending JP2015110590A (ja) | 2007-12-28 | 2014-12-26 | 抗細胞増殖化合物およびその使用方法 |
| JP2017028106A Pending JP2017141227A (ja) | 2007-12-28 | 2017-02-17 | 抗細胞増殖化合物およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014264770A Pending JP2015110590A (ja) | 2007-12-28 | 2014-12-26 | 抗細胞増殖化合物およびその使用方法 |
| JP2017028106A Pending JP2017141227A (ja) | 2007-12-28 | 2017-02-17 | 抗細胞増殖化合物およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9808512B2 (enExample) |
| EP (1) | EP2224946B1 (enExample) |
| JP (3) | JP2011509248A (enExample) |
| CA (1) | CA2710920A1 (enExample) |
| WO (1) | WO2009086516A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8599383B2 (en) | 2009-05-06 | 2013-12-03 | The Regents Of The University Of California | Optical cytometry |
| EP2739937B1 (en) * | 2011-08-02 | 2023-03-01 | The Regents of The University of California | Rapid, massively parallel single-cell drug response measurements via live cell interferometry |
| CA2853204A1 (en) * | 2011-12-16 | 2013-06-20 | Kalos Therapeutics, Inc. | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases |
| ES2671799T3 (es) | 2013-05-24 | 2018-06-08 | The Regents Of The University Of California | Identificación de linfocitos T deseables por cambio en respuestas de masa |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208218A (en) * | 1988-09-19 | 1993-05-04 | Ludwig Institute For Cancer Research | T cell growth factor glycoproteins |
| US6376257B1 (en) * | 1997-04-24 | 2002-04-23 | University Of Rochester | Detection by fret changes of ligand binding by GFP fusion proteins |
| EP1301612A2 (en) * | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| US20030203373A1 (en) | 2002-02-20 | 2003-10-30 | Wolf-Dieter Schleuning | Method for identifying a pharmacologically active substance |
| US20040016004A1 (en) * | 2002-04-01 | 2004-01-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 238P1B2 useful in treatment and detection of cancer |
| AU2003268531A1 (en) | 2002-09-06 | 2004-03-29 | University Of South Florida | Materials and methods for treatment of allergic diseases |
| US7488713B2 (en) * | 2004-03-18 | 2009-02-10 | University Of South Florida | Cancer treatment using C-type natriuretic peptides |
| US6943147B2 (en) | 2003-03-19 | 2005-09-13 | University Of South Florida | Cancer treatment using proANP peptides |
| EP1727556A2 (en) | 2004-02-17 | 2006-12-06 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
-
2008
- 2008-12-29 JP JP2010540923A patent/JP2011509248A/ja active Pending
- 2008-12-29 US US12/345,023 patent/US9808512B2/en not_active Expired - Fee Related
- 2008-12-29 WO PCT/US2008/088438 patent/WO2009086516A1/en not_active Ceased
- 2008-12-29 EP EP08868377.6A patent/EP2224946B1/en not_active Not-in-force
- 2008-12-29 CA CA2710920A patent/CA2710920A1/en not_active Abandoned
-
2014
- 2014-12-26 JP JP2014264770A patent/JP2015110590A/ja active Pending
-
2017
- 2017-02-17 JP JP2017028106A patent/JP2017141227A/ja active Pending
- 2017-11-06 US US15/804,881 patent/US20180078617A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2941768T3 (es) | Compuestos de 2H-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (TLR7) y métodos y usos para los mismos | |
| JP7770607B2 (ja) | ヘテロタンデム二環式ペプチド複合体 | |
| JP2023099069A (ja) | Ｔｌｒ７／８アゴニスト化合物の切断可能なコンジュゲート、その調製方法および使用 | |
| WO1999011659A1 (en) | Novel cyclic tetrapeptide derivatives and medicinal use thereof | |
| JP2017513826A5 (enExample) | ||
| JP2023538071A5 (enExample) | ||
| JP2018536431A5 (enExample) | ||
| US20110123988A1 (en) | Antisense compounds and methods for diagnostic imaging | |
| JP2017006120A5 (enExample) | ||
| JP2014506135A5 (enExample) | ||
| RU2007136026A (ru) | Варианты ил-21 | |
| JPWO2019230645A5 (enExample) | ||
| CN1545423A (zh) | 用于抑制转移或预防恶性肿瘤复发的含有多糖偶联物的药物组合物 | |
| WO2008031016A3 (en) | Heterocyclic ligands for integrin imaging and therapy | |
| RU2019143854A (ru) | Лечебное соединение | |
| CA3087761A1 (en) | Proteinaceous molecules and uses therefor | |
| JP2022542448A5 (enExample) | ||
| JP2014510699A5 (enExample) | ||
| JP2021506800A5 (enExample) | ||
| JP2018537433A5 (enExample) | ||
| JP2017529386A5 (enExample) | ||
| ES2744474T3 (es) | Fragmentos polipeptídicos de168A-T2 y composiciones que los comprenden para uso en el tratamiento del cáncer | |
| JP2008523067A5 (enExample) | ||
| US20250228951A1 (en) | Novel-peptide-based anticancer immunotherapeutic agent | |
| EP2545171A4 (en) | HJURP PEPTIDES AND VACCINES CONTAINING THEM |